In one study, 33% of patients with genotype 1 HCV infection and insulin resistance (defined as homeostasis model assessment of insulin resistance [HOMA-IR] > 2) achieved sustained virological response (SVR) after interferon and ribavirin treatment,

compared to 61% of those without insulin resistance.[11] In in vitro studies, insulin resistance increases viral replication and the production of lipoviroparticles. With this background, a few groups have tested the possibility of controlling Inhibitor Library insulin resistance to enhance the effect of HCV treatment. In one study, 123 patients with genotype 1 HCV infection and HOMA-IR > 2 were randomized to receive metformin 850 mg three times daily or placebo, together with peginterferon and ribavirin for 48 weeks.[12] By intention-to-treat analysis, SVR was achieved in 53% in the metformin arm and 42% in the placebo arm, a non-significant difference. Subgroup analysis showed a possible benefit of metformin in female subjects (58% vs 29%, P = 0.031). Another study in patients with genotype 4 HCV infection showed that the addition of pioglitazone might increase the SVR rate (60% vs 39%; P = 0.04).[13] Though promising, these were small studies with narrow ethnic and genotype background. More studies are required before the use of insulin sensitizers to improve HCV treatment

can be buy Ganetespib recommended. Closely associated with the issue of diabetes is the effect of lipids on HCV treatment. PRKACG In a post hoc analysis of the IDEAL trial (Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy), elevated baseline low density lipoprotein-cholesterol, reduced high density lipoprotein-cholesterol, and the use of statins were associated with higher SVR rates.[14] Besides, statin when used alone has been shown to reduce HCV RNA by 1–2 log IU/mL.[15] Once again, community screening studies from Taiwan provided important data on the epidemiology of viral hepatitis. The paper by Liu et al. firmly established the positive association between HCV infection

and diabetes in the general population (Fig. 1). Metabolic factors modify the natural history of chronic hepatitis C and may be exploited to improve antiviral therapy. Further studies along this line will increase our understanding of the pathophysiology of HCV infection and identify new targets for treatment. “
“It has been said that “lactulose is a many splendored thing . . . with many other beneficial actions in its bag of tricks.”1 Is the routine use of lactulose as prophylaxis for hepatic encephalopathy following an acute variceal bleed another “trick” to be pulled out of the proverbial bag? The use of lactulose has long been applied in the setting of constipation. In 1966, lactulose was introduced in the treatment of hepatic encephalopathy by Bircher et al.